Table 1 Clinical differences between genders
From: Glucocorticoid use in psoriatic arthritis and treatment outcomes: does the gender have a role?
Variable | Female (n = 96) | Male (n = 45) | P value |
|---|---|---|---|
Age (mean, SD) | 50.44 ± 13.76 | 46.87 ± 12.76 | 0.144 |
Symptom duration (mean, SD) | 2.96 ± 6.05 | 3.77 ± 6.51 | 0.474 |
DIP involvement (n,%) | 14 (14%) | 3 (6%) | 0.142 |
Large joint involvement (n,%) | 24 (25%) | 11 (24%) | 0.560 |
TJS (mean, SD) | 4.76 ± 2.67 | 3.98 ± 3.11 | 0.127 |
SJS (mean, SD) | 3.74 ± 1.99 | 3.02 ± 2.2 | 0.056 |
VAS (mean, SD) | 5.94 ± 1.13 | 5.69 ± 1.04 | 0.214 |
DAS 28 (mean, SD) | 3.56 ± 0.62 | 3.36 ± 0.75 | 0.088 |
CRP (mg/dL) (mean, SD) | 13.7 ± 13.5 | 13.7 ± 12.2 | 0.996 |
DAPSA (mean, SD) | 21.80 ± 6.79 | 19.97 ± 8.12 | 0.164 |
Uric acid (mg/dL) (mean, SD) | 4.67 ± 1.33 | 6.53 ± 1.38 | 0.000* |
Enthesitis (n, %) | 11 (11%) | 6 (13%) | 0.473 |
Dactylitis (n, %) | 9 (9%) | 3 (6%) | 0.429 |
Axial involvement (n, %) | 19 (19%) | 11 (24%) | 0.337 |
Cervical vertebrae involvement (n, %) | 10 | 3 | 0.354 |
Sacroiliitis (uni-bilateral) (n, %) | 11 (11%) | 12 (26%) | 0.023* |
Nail psoriasis (n, %) | 8 (8%) | 0 (0%) | 0.042 |
Pustular psoriasis (n, %) | 3 (3%) | 2 (4%) | 0.513 |
Non-psoriasis (n, %) | 8 (8%) | 2 (4%) | 0.325 |
TNF inhibitor (n, %) | 16 (16%) | 17 (37%) | 0.006* |
GC use (n, %) | 42 (43%) | 13 (28%) | 0.66 |
GC dose < 7.5 mg (n) | 38 | 9 | 0.054 |
7.5–30 mg (n) | 4 | 4 | |
> 30 mg (n) | 0 | 0 | |
GC duration | 0.159 | ||
< 3 months (n) | 37 | 10 | |
> 3 months (n) | 5 | 3 |